Skip to main content
FBIO
NASDAQ Life Sciences

Fortress 10-Q: Q3 Revenue $19.2M, $7.9M Net Loss, $152.2M Cash and No Parent Debt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.954
Mkt Cap
$66.368M
52W Low
$1.79
52W High
$4.53
52W Position info
9.2% above low
Off High info
57% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

FBIO is trading near its 52-week low of $1.79 (9.2% above the low).

Summary

Fortress's Q3 10-Q confirms $19.2 million of revenue (up 9%) but a $(7.9) million loss attributable to common stockholders, alongside $152.2 million of cash and no parent-level debt after repaying Oaktree. The company remains locked out of Form S-3 while preferred dividends stay paused.


Key Events · Earnings and Guidance · FBIO

  • Q3 Revenue Grows 9% to $19.2M

    Net revenue was $19.2 million versus $17.6 million a year earlier, with product revenue of $18.9 million driven by Emrosi at $9.0 million versus $4.9 million, partly offset by Qbrexza falling $1.8 million.

  • Quarter Swings to $7.9M Net Loss

    Net loss attributable to common stockholders was $(7.9) million, or $(0.23) per share, versus $3.7 million of income, or $0.13 per share, a year earlier; the prior period included a $17.7 million other-income gain that did not repeat.

  • Cash of $152.2M, Oaktree Repaid

    Consolidated cash reached $152.2 million at September 30, 2026, of which $114.1 million sits at the parent and private subsidiaries; the Oaktree facility was paid off for $15.6 million on September 30, 2026, leaving Journey's $25.6 million SWK term loan as the only debt.

  • Preferred Dividend Pause Blocks Form S-3

    Series A dividends remain paused, with $18.1 million of undeclared dividends accrued, so the company cannot use its $42.1 million 2024 shelf and would need a Form S-1 or private placement to raise equity.


Analysis · FBIO · Life Sciences

The headline numbers were already out in this morning's 8-K, but the 10-Q is where the quality of the quarter shows. Revenue of $19.2 million was up 9% on Emrosi's ramp to $9.0 million, yet the quarter flipped to a $(7.9) million loss attributable to common stockholders from $3.7 million of income a year earlier — the prior-year quarter carried a $17.7 million fair-value gain on the Crystalys stake that did not repeat, and Journey booked a $1.7 million charge above its accrual to settle a vendor dispute. The balance sheet is the real story: $152.2 million of consolidated cash, $114.1 million of it at the parent and private subsidiaries, and the Oaktree facility repaid in full on September 30, 2026, leaving only Journey's $25.6 million SWK term loan. Against that, the company still cannot use Form S-3 because Series A preferred dividends remain paused, with $18.1 million of undeclared dividends accrued — so any equity raise would be slower and costlier than a shelf takedown.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FBIO was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.4M. The 52-week trading range was $1.79 to $4.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FBIO - Latest Insights

FBIO
Aug 13, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $1.95 info
Change: -$1.00 (-34%) info
Market Cap: $66.368M info
FBIO
May 14, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.34
Real-time Price: $1.95 info
Change: -$0.3862 (-17%) info
Market Cap: $66.368M info
FBIO
May 14, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.34
Real-time Price: $1.95 info
Change: -$0.3862 (-17%) info
Market Cap: $66.368M info
FBIO
May 14, 2026, 4:20 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.33
Real-time Price: $1.95 info
Change: -$0.3762 (-16%) info
Market Cap: $66.368M info
FBIO
Mar 31, 2026, 5:05 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.85
Real-time Price: $1.95 info
Change: -$0.8918 (-31%) info
Market Cap: $66.368M info